| Expression pattern: |
UP |
| Associated gene: |
TOX3, YAP, TAZ, E-cadherin, vimentin, ZEB1 |
| Associated microRNA: |
miR-135b-3p |
| Biological function: |
hsa_circ_0017109 promotes LUAD/NSCLC progression by enhancing cell proliferation, migration, invasion and metastasis and by suppressing apoptosis; melatonin inhibits LUAD progression partly by reducing hsa_circ_0017109 expression. |
| Molecular mechanism: |
hsa_circ_0017109 acts as a ceRNA that sponges miR-135b-3p, thereby regulating TOX3 expression and affecting Hippo signaling and EMT pathways; melatonin suppresses this axis by inhibiting hsa_circ_0017109. |
| Biological pathway or process: |
ceRNA regulation (other); Hippo/YAP (promotes); EMT (promotes); proliferation (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); metastasis (promotes); drug resistance (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Wound Healing Assay; Transwell Assay; Western Blot; In Vivo Animal Model; H&E Staining; Survival Analysis |
| Clinical significance: |
hsa_circ_0017109 expression was positively correlated with clinical stage, tumor size, and overall survival, and may act as a promising diagnostic and prognostic biomarker for NSCLC samples. |
| Description: |
hsa_circ_0017109 is up-regulated in LUAD/NSCLC and is associated with more aggressive clinicopathological features. Functionally, it promotes lung cancer cell proliferation, migration, invasion and metastasis while reducing apoptosis. Mechanistically, melatonin suppresses LUAD progression by inhibiting hsa_circ_0017109, which releases miR-135b-3p to downregulate TOX3 and inhibit Hippo signaling and EMT-related programs. |
| Confidence score: |
0.7901 |